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1. Data {#sec1}
=======

Here we display data in [Table 1](#tbl1){ref-type="table"}, which illustrates the mass spectrometry tuning parameters of MPPZ-derivatives of catechol estrogens, shown by their exact theoretical and observed masses. In [Table 2](#tbl2){ref-type="table"}, data demonstrating the limit of detection that can be achieved for analytes following derivatization are given for unextracted standards, alongside observed retention times from chromatographic interpretation, [Fig. 1](#fig1){ref-type="fig"}. Finally, the recoveries of catechol estrogens from plasma following solid-phase extraction (SPE) are displayed in [Table 2](#tbl2){ref-type="table"}, with associated data describing matrix effects.Table 1Mass spectrometric analysis of MPPZ derivatized catechol estrogens.Table 1Analyte-MPPZAccurate mass precursor ion *m*/*z*Theoretical product ion massObserved product ion mass *m*/*z*Product ion Δ ppmCollision energy (V)Collision exit cell potential (V)De-clustering potential (V)2OHE1565.2662^a^251.1269\
^b^58.0656^a^251.1276\
^b^58.06512.78\
8.6159.0\
129.010.0\
10.0130.0\
130.04OHE1565.2662^a^251.1269\
^b^58.0656^a^251.1274\
^b^58.06730.39\
29.27^c^59.0\
129.010.0\
10.0130.0\
130.02OHE2567.2819^a^251.1269\
^b^281.1249^a^251.1274\
^b^281.12521.99\
1.0661.0\
61.022.0\
22.0166.0\
166.04OHE2567.2819^a^251.1269\
^b^281.1249^a^251.1265\
^b^281.12511.59\
0.7161.0\
61.022.0\
22.0166.0\
166.0^13^C~6-~4OHE1571.2864^a^251.1269\
^b^58.0656^a^251.1268\
^b^58.06610.39\
1.7250.0\
100.015.0\
15.0136.0\
136.0^13^C~6-~2OHE2573.3020^a^251.1269\
^b^281.1249^a^251.1269\
^b^281.12510.00\
0.7150.0\
50.015.0\
15.0136.0\
136.0[^1]Table 2Indices of extraction performance.Table 2Analyte-MPPZInternal standardUnextracted LOD (pg mL^−1^)Retention time (s) (min)MCX^®^ recovery (%)Generic IonSup (%)Optimized IonSup (%)2OHE1^13^C~6~-4OHE12017.38/17.7572 ± 3−94 ± 6−72 ± 24OHE1^13^C~6~-4OHE12017.62/17.9068 ± 2−94 ± 2−73 ± 42OHE2^13^C~6~-2OHE22016.03/17.0069 ± 2−93 ± 8−69 ± 84OHE2^13^C~6~-2OHE22016.5862 ± 4−95 ± 9−71 ± 6[^2]Fig. 1Total and extracted ion chromatograms of (A) methylpiperazine (MPPZ) derivatives of catechol estrogens, (B) The estrone metabolites 2-Hydroxyestrone (2OHE1), 4-Hydroxyestrone (4OHE1), and (C) the estradiol metabolites 2-Hydroxyestradiol (2OHE2), 4-Hydroxyestradiol (4OHE2) at 1000 pg mL^−1^. Figure illustrating challenges in separating catechol metabolites by mass transitions and retention time (min).Fig. 1

Catechol estrogens (2 and 4-hydroxy-estrogens) are challenging metabolites to analyze by LC-MS/MS [@bib2], [@bib3]. Common analytical challenges arise due to their unstable nature and short half-lives [@bib4]. Derivatization to 1-(2, 4-dinitrophenyl)-4,4-dimethylpiperazinium (MPPZ) derivatives has been successfully applied for analysis of estrone, estradiol, 16-hydroxy and 2 and 4 methoxyestrogens [@bib1]. Here the successes and pitfalls of applying this approach to analyse catechol estrogens are described. For 2 &4-hydroxyestrogens, MPPZ derivatives were generated with the original protocol [@bib1] but with poor yield, with insufficient detection upon lowering the concentrations (\<500 pg mL^−1^). Comparison of various derivatization base catalysts (sodium bicarbonate, triethylamine, pyridine, ammonium hydroxide and *N*-diethylaniline) was key in achieving efficient derivatization. Modification of the base catalyst to *N*-diethylaniline enhanced PPZ derivatization with catechol estrogens, showing ×500 increase in peak area response, but this approach caused reduction of signals of the 9 other estrogens (E1, E2, 16-hydroxy and 4 and 2-methoxy-estrogens) within this sex steroid pathway. Combinations of base catalysts were also tested to create a holistic approach. However, derivatization of the catechol metabolites and additional 9 estrogens were only successful in separate reactions.

Structural identification of precursor and product ions for the catechol derivates were achieved by high resolution MS and multiple reaction monitoring for quantitation established by triple quadrupole MS, [Table 1](#tbl1){ref-type="table"}.

Double derivatives of these compounds were not seen, but isomeric mono-derivatives were observed, believed due to the possibility of either of the A-ring hydroxyl groups reacting. To achieve the highest degree of chromatographic resolution of isomers and isotopologues, a C18_PFP (2.1 × 150mm) was coupled to a C18_PFP (2.1 × 20mm). The reduction of oven temperature from 25 to 20 °C also aided in resolving the catechol estrogen derivative peaks ([Fig. 1](#fig1){ref-type="fig"}).

Data illustrated that recovery of catechol estrogens (pre vs post-spiked PA) from Oasis MCX cartridges, [Table 2](#tbl2){ref-type="table"} was acceptable (2OHE1 73%, 4OHE1 66%, 2OHE2 68% & 4OHE 64%). However, unfortunately significant ion suppression (unextracted peak area vs extracted + derivatized estrogen peak area) was present for all catechol metabolites recovered from plasma (2OHE1 by 94%, 4OHE1 96.1%, 2OHE2 94.7% & 4OHE2 96.5%), [Table 2](#tbl2){ref-type="table"}. Additional clean up steps utilizing aqueous methanol or acetonitrile (0--70% v/v) improved ion suppression but not to an acceptable degree; the least ion suppression was observed with washes of 60%v/v MeOH (Ion suppression: 2OHE1 by 80.5%, 4OHE1 78.9%, 2OHE2 79.9% & 4OHE2 79.7%) and 30% ACN (2OHE1 by 80%, 4OHE1 88%, 2OHE2 77% & 4OHE2 86%). Further modification of elution solvent (70--100% v/v MeOH) did not decrease ion suppression sufficiently with the optimal wash of 95% v/v MeOH still showing suppression of ∼80% (2OHE1 85%, 4OHE1 95%, 2OHE2 78% & 4OHE2 71%). Thus, an alternative extraction protocol for use alongside the modified MPPZ derivatization protocol for 2, 4 hydroxy estrogens is required.

2. Experimental design, materials, and methods {#sec2}
==============================================

2.1. Materials {#sec2.1}
--------------

2-Hydroxyestrone (2OHE1), 4-hydroxyestrone (4OHE1), 2-hydroxyestradiol (2OHE2), 4-hydroxyestradiol (4OHE2) were from Steraloids, Inc (Newport, USA). 13,14,15,16,17,18-^13^C~6~-4-Hydroxyestrone (^13^C~6~-4OHE1) and 13,14,15,16,17,18-^13^C~6~-2-hydroxyestradiol (^13^C~6~-2OHE2) were from CK Isotopes Limited (Leicestershire, UK). *N*-Diethylaniline was from Acros Organics (Geel, Belgium). All additional reagents were sourced as specified in Denver et al. [@bib1].

2.2. Methods {#sec2.2}
------------

Analysis, including assessment of extraction efficiency and ion suppression, was performed according to the approach described in Denver et al. [@bib1] and modifications for catechol estrogens reported below.

### 2.2.1. Instrumentation {#sec2.2.1}

Structures of fragment ions formed from estrogen derivatives were determined by high resolution MS using a SYNAPT G2Si instrument (Waters Corp, Manchester, UK) fitted with an ESI source in positive mode [@bib1]. Method development was performed using a Shimadzu Nexera X2 LC (Shimadzu, Kyoto, Japan) coupled to a Sciex 6500 + Mass Spectrometer (Sciex, Warrington, UK) operated in positive electrospray (ESI).

### 2.2.2. Chromatographic conditions {#sec2.2.2}

Estrogen metabolites were analyzed both individually and in a mixed solution to confirm separation. Two Ace Excel 2 C18-PFP column (150 × 2.1 mm, 2 μm + 20 × 2.1 mm, 2 μm; HiChrom, Reading, England) were coupled at an oven temperature of 20 °C. A gradient solvent system of water: acetonitrile (90:10), containing formic acid (FA; 0.1%, 0.5 mL/min) was diverted to waste for the initial 9 minutes followed by elution for a further 4 minutes at 90:10, then with a gradient over 3 minutes until final conditions of water: acetonitrile (90:10) containing FA (0.1%, 0.5 mL/min) were achieved. Injection volume was 30 μL.

### 2.2.3. Derivatization and optimization {#sec2.2.3}

The following protocol was applied for derivatization PPZ stock (10 μL; 1mg mL^−1^), *N*-diethylaniline (10 μL) and acetone (70 μL) were added to the catechol estrogen standards and was capped and incubated (60 °C, 1 h). Reagents were reduced to dryness at 40 °C under oxygen free nitrogen (OFN). The dried residue was incubated (40 °C, 2 h) with CH~3~I (100 μL). The mixture was reduced to dryness under OFN and dissolved in H~2~O/CH~3~CN (70:30; 70 μL).

### 2.2.4. Extraction and optimization {#sec2.2.4}

SPE using Oasis^®^ MCX (3 cc/60 mg, Waters, Wilmslow, UK) cartridges was applied under gravity. Prior to loading the sample, cartridges were conditioned and equilibrated with methanol (2 mL), followed by water (2 mL). The diluted sample (0.5 mL plasma + 0.5mL water (or 1 mL water for standards) + 200 pg mL^−1^ Internal Standard) was loaded and allowed to pass through the cartridges and the eluate discarded. The cartridges were washed with aqueous FA (2% v/v, 2 mL). A second wash of methanol (60% v/v, 2 mL) was applied with the eluate discarded. Steroids were eluted in methanol (95%; 2 mL). Extracts were reduced to dryness under OFN (40 °C) and the residues were derivatized as above.

Transparency document {#appsec1}
=====================

The following is the transparency document related to this article:Multimedia component 1

We would like to thank the BBSRC iCASE award (BB/N503691/1) for PhD funding and to the Graham Wilson Travel Scholarship for their award to fund commuting costs for two years of the project. We would also like to thank the Wellcome Trust (202794/Z/16/Z), NC3Rs (NC/L00108X/1) and The BHF (PG/15/63/31659 and RG/16/2/32153) for funding. We are also grateful to the staff of the Mass Spectrometry Core, Edinburgh Clinical Research Facility for expert scientific help.

Transparency document associated with this article can be found in the online version at <https://doi.org/10.1016/j.dib.2019.103740>.

[^1]: ^a^quantifier ion, ^b^qualifier ion, ^c^Fragments with low signal intensity following infusion generated higher ppm values; Entrance potential = 10V; mass to charge (*m*/*z*); Mass error (Δppm); Voltage (V); 2-hydroxyestrone (2OHE1); 4-hydroxyestrone (4OHE1); 2-hydroxyestradiol (2OHE2); 4-hydroxyestradiol (4OHE2); 13,14,15,16,17,18-^13^C~6~-4-hydroxyestrone (^13^C~6~-4OHE1); 13,14,15,16,17,18-^13^C~6~-2-hydroxyestradiol (^13^C~6~-2OHE2); MPPZ, 1-(2, 4-dinitrophenyl)-4,4-dimethylpiperazine.

[^2]: 2-hydroxyestrone (2 OHE1); 4-hydroxyestrone (4 OHE1); 2-hydroxyestradiol (2 OHE2); 4-hydroxyestradiol (4 OHE2); 13,14,15,16,17,18-^13^C~6-~4-hydroxyestrone (^13^C~6~-4OHE1); 13,14,15,16,17,18-^13^C~6~-2-hydroxyestradiol (^13^C~6~-2OHE2); MPPZ, 1-(2, 4-dinitrophenyl)-4,4-dimethylpiperazine; LOD, Limit of detection; min, minutes; MCX, Mixed Cation Exchange; IonSup, Ion Suppression.
